NCT07157735 - A Trial to Test the Use of Dapansutrile, an Anti-inflammatory Medication, in People With Parkinson's Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2025

Primary Completion Date

August 31, 2027

Study Completion Date

February 29, 2028

Conditions

Parkinson Disease

Interventions

DRUG

dapansutrile

Dapansutrile tablets administered for 26 weeks, starting at 1,000 mg daily (500 mg twice daily) for 4 weeks, escalated to 2,000 mg daily (1,000 mg twice daily) thereafter.

DRUG

placebo

Matched placebo tablets administered for 26 weeks, admistered as per the active treatment.

Trial Locations (1)

CB2 0PY

John Van Geest Centre for Brain Repair, Cambridge